HIV-HCV co-infected subjects are at risk of liver fibrosis which may be linked to immune imbalances. Direct-acting antivirals (DAAs) represent the mainstay of HCV treatment in co-infected individuals, yet their effects on immune cell populations playing a role in fibrogenesis is unknown. We assessed gamma delta T-cell phenotype and function, Treg and Th17 frequencies, as well as gamma-globulins and B-cell activation in 47 HIV-HCV co-infected and 35 HCV mono-infected individuals prior to and following DAA treatment (SVR12). Gamma delta T-cell activation decreased in both groups yet persisted at higher levels in the HIV-HCV co-infected subjects. No differences were registered in terms of gamma delta T-cell function. Of note, the V delta 2/Th17 ratio, inversely linked to liver damage, increased significantly in the two groups upon treatment, yet a negative correlation between the V delta 2/Th17 ratio and liver function enzymes was found in the co-infected subjects alone. B-cell activation and gamma-globulin levels decreased in both settings, yet B-cell activation remained higher in the HIV-HCV co-infected individuals. In HIV-HCV co-infected and HCV mono-infected participants, the effect of DAA was limited to gamma delta T- and B-cell activation as well as gamma-globulin concentrations and the V delta 2/Th17 ratio, with no changes in gamma delta T-cell function and Treg frequencies. Importantly, gamma delta T- and B-cell activation remained at higher levels in the co-infected individuals than in those with HCV mono-infection alone. The persistence of such alterations within these cell subsets may be associated with the risk of hepatic and extrahepatic complications.

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects / V. Bono, C. Tincati, L. Van Den Bogaart, E.S. Cannizzo, R. Rovito, M. Augello, A. De Bona, A. D'Arminio Monforte, L. Milazzo, G. Marchetti. - In: VIRUSES. - ISSN 1999-4915. - 14:8(2022 Aug), pp. 1594.1-1594.10. [10.3390/v14081594]

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects

V. Bono
Primo
;
C. Tincati;L. Van Den Bogaart;E.S. Cannizzo;R. Rovito;M. Augello;A. D'Arminio Monforte;
2022

Abstract

HIV-HCV co-infected subjects are at risk of liver fibrosis which may be linked to immune imbalances. Direct-acting antivirals (DAAs) represent the mainstay of HCV treatment in co-infected individuals, yet their effects on immune cell populations playing a role in fibrogenesis is unknown. We assessed gamma delta T-cell phenotype and function, Treg and Th17 frequencies, as well as gamma-globulins and B-cell activation in 47 HIV-HCV co-infected and 35 HCV mono-infected individuals prior to and following DAA treatment (SVR12). Gamma delta T-cell activation decreased in both groups yet persisted at higher levels in the HIV-HCV co-infected subjects. No differences were registered in terms of gamma delta T-cell function. Of note, the V delta 2/Th17 ratio, inversely linked to liver damage, increased significantly in the two groups upon treatment, yet a negative correlation between the V delta 2/Th17 ratio and liver function enzymes was found in the co-infected subjects alone. B-cell activation and gamma-globulin levels decreased in both settings, yet B-cell activation remained higher in the HIV-HCV co-infected individuals. In HIV-HCV co-infected and HCV mono-infected participants, the effect of DAA was limited to gamma delta T- and B-cell activation as well as gamma-globulin concentrations and the V delta 2/Th17 ratio, with no changes in gamma delta T-cell function and Treg frequencies. Importantly, gamma delta T- and B-cell activation remained at higher levels in the co-infected individuals than in those with HCV mono-infection alone. The persistence of such alterations within these cell subsets may be associated with the risk of hepatic and extrahepatic complications.
B-cells; DAA; HCV; HIV; Th17-cells; Treg cells; liver damage; γδ T-cells
Settore MED/17 - Malattie Infettive
22-lug-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
viruses-14-01594-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.23 MB
Formato Adobe PDF
1.23 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/948335
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact